back to open calls

Life Sciences Innovative Manufacturing Fund (LSIMF)

Health & Life Sciences
Manufacturing & Materials
Project Size:

The Life Sciences Innovative Manufacturing Fund (LSIMF) is part of the Global Britain Investment Fund, of which £354 million will support life sciences manufacturing.

The LSIMF will provide £60 million in capital grants for investment in the manufacture of:

  • human medicines (drug substance and drug product)
  • medical diagnostics
  • MedTech products

We particularly encourage applications from companies ready to deploy their emerging technologies at scale in commercial manufacturing.

Your manufacturing investment must relate to the manufacture of: Human medicines (this includes both the manufacture of active pharmaceutical ingredients (API) / drug substance and finished product / drug product). The fund is open to applications across the breadth of types of MHRA licensed medicines for human use, OR

Diagnostics – for both disease identification and monitoring in human health, OR

Medical devices – all types of medical devices related to human health

Your project must: Be a manufacturing project: this could be manufacturing product for clinical trials or for commercial sale, AND

Be located in the UK, AND

Have a total investment value of more than £12 million

Your project can: Be for the upgrade or expansion of an existing facility or the establishment of a new manufacturing facility

Applicants will be prioritised based on their alignment to the fund’s objectives:

  1. Creating economic opportunity through investments that will provide high-wage, high-skilled jobs.
  2. Deploying cutting-edge innovations (at both pilot and commercial scale) which can be embedded in either the product itself or the manufacturing process.
  3. Increasing health resilience, either through increased domestic capacity or by providing flexible capabilities that can be re-deployed in some way in a future health emergency.
  4. Minimising impact on the environment, which might include reduction in input resources or using alternative input materials to become more sustainable or support the government’s net zero target.

Applications are welcome from companies developing highly innovative products such as:

  • complex medicines such as advanced therapies and nucleic acid therapies, non-biological complex medicines and medicines that require complex delivery mechanisms
  • innovative medical technologies such as nanomedicine applications in imaging, sensing, diagnosis, and delivery through medical devices, 5G enabled devices, smarter pacemakers and 3D printed devices
  • diagnostics such as ‘breathalysers’ for the early detection of inflammatory and infectious diseases and ‘lab on a chip’

In addition, we particularly welcome applications that include the adoption of innovative process technologies, such as:

  • flexible manufacturing enabling product switching
  • scalable manufacturing
  • novel manufacturing processes
  • technologies that will minimise your impact on the environment
  • continuous manufacturing, both for commercial scale and clinical trials manufacturing
  • digital twins, which harness the power of data analytics and modelling to optimise manufacturing processes
Interested in this call? Book a free consultation with our team
Book a Consultation
+44 (0) 1925 506 100
Contact Us
Thank you! We will be in touch shortly.
Oops! Something went wrong while submitting the form.